Keywords: Cardiorenal syndrome; Chronic heart failure; Diabetic kidney disease; Renin-angiotensin system; Empagliflozin;
مقالات ISI (ترجمه نشده)
مقالات زیر هنوز به فارسی ترجمه نشده اند.
در صورتی که به ترجمه آماده هر یک از مقالات زیر نیاز داشته باشید، می توانید سفارش دهید تا مترجمان با تجربه این مجموعه در اسرع وقت آن را برای شما ترجمه نمایند.
در صورتی که به ترجمه آماده هر یک از مقالات زیر نیاز داشته باشید، می توانید سفارش دهید تا مترجمان با تجربه این مجموعه در اسرع وقت آن را برای شما ترجمه نمایند.
Keywords: Cost-effectiveness; Cost-utility study; Economic evaluation; Empagliflozin; SGLT2 inhibitor; Diabetes mellitus;
Keywords: Canagliflozin; Empagliflozin; Extended ratio subtraction; Linagliptin; Metformin; Ratio difference; UV spectrophotometry; Validation;
Keywords: type 2 diabetes; sodium-glucose cotransporter 2 inhibitors; cardiovascular safety; canagliflozin; dapagliflozin; empagliflozin; diabète de type 2; inhibiteurs du cotransporteur sodium-glucose de type 2; innocuité sur le plan cardiovasculaire; canagliflo
Keywords: Empagliflozin; Heart failure; SGLT2 inhibitor; Type 2 diabetes mellitus; CKD; chronic kidney disease; HF; heart failure; SGLT2; sodium glucose co-transporter 2; T2DM; type 2 diabetes mellitus;
Keywords: Cardiovascular outcomes; Empagliflozin; Mechanisms; Sodium glucose cotransporter 2 inhibitors;
Keywords: Empagliflozin; Metformin; Simultaneous equation; Chemometry; Partial least squares; Pharmaceutical preparation
Keywords: Diabetes mellitus tipo 2 (DM2); Cotransportador sodio-glucosa tipo 2 (SGLT2); Inhibidores del SGLT2 (iSGLT2); Dapagliflozina; Canagliflozina; Empagliflozina; GuÃas de práctica clÃnica; Red de Grupos de Estudio de la Diabetes en; Atención Primaria de l
Keywords: SGLT2 Inhibitors; Dapagliflozin; Canagliflozin; Empagliflozin; CANVAS; CREDENCE; DECLARE-TIMI 58; Cardiovascular outcomes; Nonglycemic benefit of SGLT2 inhibitors;
Keywords: Empagliflozin; Type 2 diabetes mellitus; SGLT-2 inhibitors; Empagliflozina; Diabetes mellitus tipo 2; Inhibidores de transportador sodio glucosa tipo 2;
Keywords: Empagliflozina; Diabetes mellitus tipo 2; Inhibidores de transportador sodio glucosa tipo 2; Empagliflozin; Type 2 diabetes mellitus; SGLT-2 inhibitors;
Keywords: empagliflozin; once daily; pharmacodynamics; pharmacokinetic properties; twice daily;
Keywords: canagliflozin; dapagliflozin; empagliflozin; sodium-glucose co-transporter 2 inhibitor;
Keywords: diabetes; DPP-4 inhibitor; drug-drug interaction; empagliflozin; linagliptin; SGLT2 inhibitor;
Empagliflozin rescues diabetic myocardial microvascular injury via AMPK-mediated inhibition of mitochondrial fission
Keywords: Empagliflozin; Mitochondrial fission; Microvascular; CMECs; AMPK;
SGLT2 inhibitors with cardiovascular benefits: Transforming clinical care in Type 2 diabetes mellitus
Keywords: Type 2 diabetes mellitus; Empagliflozin; Cardiovascular risk reduction; Improved renal outcomes; Glycaemic control;
Precision medicine approach: Empagliflozin for diabetic cardiomyopathy in mice with aldehyde dehydrogenase (ALDH) 2â¯*â¯2 mutation, a specific genetic mutation in millions of East Asians
Keywords: 4-hydroxy-2-nonenal; Type-2 diabetes; Aldehyde dehydrogenase-2; Empagliflozin; Cardiac function; ALDH2â¯*â¯2 mutant mice;
Sodium-dependent glucose transporters (SGLT) in human ischemic heart: A new potential pharmacological target
Keywords: Ischemic heart disease; Myocardial disease; Cardiac hypertrophy; Heart failure; Empagliflozin; SGLT1; SGLT2;
EMPA-REG OUTCOME: The Endocrinologist's Point of View
Keywords: Cardiovascular outcomes; Empagliflozin; EMPA-REG OUTCOME; Major adverse cardiovascular events; Type 2 diabetes mellitus;
EMPA-REG OUTCOME: The Cardiologist's Point of View
Keywords: Cardiac workload; Cardiovascular outcomes; Empagliflozin; Myocardial oxygen consumption; Sodium glucose cotransporter 2 inhibitors;
Empagliflozin Prevents Worsening of Cardiac Function in an Experimental Model of Pressure Overload-Induced Heart Failure
Keywords: empagliflozin; heart failure; SGLT2; sodium/glucose cotransporter 2 inhibitor; HF; heart failure; LV; left ventricular; SGLT2; sodium/glucose cotransporter 2; TAC; transverse aortic constriction;
EMPA-REG OUTCOME: The Nephrologist's Point of View
Keywords: Canagliflozin; Dapagliflozin; Empagliflozin; Renal outcomes; Renoprotection; Sodium glucose cotransporter 2 inhibitors;
Effects of reducing blood pressure on renal outcomes in patients with type 2 diabetes: Focus on SGLT2 inhibitors and EMPA-REG OUTCOME
Keywords: Blood pressure; Empagliflozin; Hypertension; Kidney; SGLT2 inhibitor; Type 2 diabetes;
SGLT2 Inhibition by Empagliflozin Promotes Fat Utilization and Browning and Attenuates Inflammation and Insulin Resistance by Polarizing M2 Macrophages in Diet-induced Obese Mice
Keywords: ALT; Alanine aminotransferase; AMPK; AMP-activated protein kinase; AST; aspartate aminotransferase; ATMs; adipose tissue macrophages; BAT; brown adipose tissue; CT; computed tomographic; DIO; high-fat-diet-induced obese; EGP; endogenous glucose production
Systematic review of metformin monotherapy and dual therapy with sodium glucose co-transporter 2 inhibitor (SGLT-2) in treatment of type 2 diabetes mellitus
Keywords: SGLT2 inhibitors; Dapagliflozin; Canagliflozin; Empagliflozin; Metformin; Type 2 diabetes mellitus; HbA1c;
Resolving the KgA1c paradox in the management of type 2 diabetes mellitus
Keywords: Canagliflozin; Dapagliflozin; Empagliflozin; KgA1c paradox; Overweight; SGLT2 inhibitors; Type 2 diabetes mellitus;
Which is the main molecular target responsible for the cardiovascular benefits in the EMPA-REG OUTCOME trial? A journey through the kidney, the heart and other interesting places
Keywords: Empagliflozin; SGLT2 inhibitors; Cardio-protection; Type 2 diabetes;
Effects of reducing blood pressure on cardiovascular outcomes and mortality in patients with type 2 diabetes: Focus on SGLT2 inhibitors and EMPA-REG OUTCOME
Keywords: Blood pressure; Diuretic; Empagliflozin; Hypertension; SGLT2 inhibitor; Type 2 diabetes;
SGLT2 inhibitors: their potential reduction in blood pressure
Keywords: Canagliflozin; dapagliflozin; empagliflozin; hypertension
A quantitative LC-MS/MS method for determining ipragliflozin, a sodium-glucose co-transporter 2 (SGLT-2) inhibitor, and its application to a pharmacokinetic study in rats
Keywords: SGLT2; Ipragliflozin; Empagliflozin; Liquid chromatography-tandem mass spectrometry;
Pharmacokinetic and Pharmacodynamic Properties and Tolerability of Single- and multiple-dose Once-daily Empagliflozin, a Sodium Glucose Cotransporter 2 Inhibitor, in Chinese Patients With Type 2 Diabetes Mellitus
Keywords: Chinese patients; empagliflozin; fasting plasma glucose; pharmacokinetics; urinary glucose excretion;
Assessing Pharmacokinetic Interactions Between the Sodium Glucose Cotransporter 2 Inhibitor Empagliflozin and Hydrochlorothiazide or Torasemide in Patients With Type 2 Diabetes Mellitus: A Randomized, Open-Label, Crossover Study
Keywords: drugâdrug interaction; empagliflozin; hydrochlorothiazide; pharmacokinetic properties; torasemide;
Empagliflozin as Add-on Therapy to Pioglitazone With or Without Metformin in Patients With Type 2 Diabetes Mellitus
Keywords: empagliflozin; glycemic control; metformin; pioglitazone; SGLT2; type 2 diabetes mellitus;
Empagliflozin as add-on to metformin plus sulphonylurea in patients with type 2 diabetes
Keywords: Empagliflozin; Glycaemic control; Metformin; SGLT2 inhibitor; Sulphonylurea;
Metabolic effects of SGLT-2 inhibitors beyond increased glucosuria: A review of the clinical evidence
Keywords: Canagliflozin; Dapagliflozin; Empagliflozin; Energy balance; Glucotoxicity; Insulin secretion; Insulin sensitivity; Type 2 diabetes
Effect of Renal Impairment on the Pharmacokinetics, Pharmacodynamics, and Safety of Empagliflozin, a Sodium Glucose Cotransporter 2 Inhibitor, in Japanese Patients With Type 2 Diabetes Mellitus
Keywords: empagliflozin; Japanese patients; pharmacodynamics; pharmacokinetics; renal impairment; SGLT2 inhibitor;
Effect of Gemfibrozil, Rifampicin, or Probenecid on the Pharmacokinetics of the SGLT2 Inhibitor Empagliflozin in Healthy Volunteers
Keywords: drug interactions; empagliflozin; organic anion transporters; uridine diphosphate glucuronosyltransferase;
Lack of Clinically Relevant Drug–Drug Interaction Between Empagliflozin, a Sodium Glucose Cotransporter 2 Inhibitor, and Verapamil, Ramipril, or Digoxin in Healthy Volunteers
Keywords: digoxin; drug–drug interaction; empagliflozin; ramipril; SGLT2 inhibitor; type 2 diabetes; verapamil